Innate Pharma logo

Innate Pharma(NASDAQ) IPHA

Market Cap$177.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-74%
5 Year-73%
1 Year-20%
1 Month-25%
$1.59
-2.45%
-0.04Today
Innate Pharma last closing stock price
MetricPriceDate
Last closeUSD 1.592026-10-01
Innate Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.47%USD 1.702026-09-24
1 month-25%USD 2.122026-09-01
3 month-11.67%USD 1.802026-07-02
Year to date-9.14%USD 1.752025-12-31
1 year-19.62%USD 1.982025-10-01
3 year-38.61%USD 2.592023-10-02
5 year-73.23%USD 5.942021-10-01
Since inception-74.1%USD 6.142019-10-18

Innate Pharma Financials at a Glance

Market Cap

$177.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€6.22M

Net Income (TTM)

-€93.57M

EPS (TTM)

-$0.59

P/E Ratio

-2.69

Dividend

$0.00

Beta (Volatility)

0.68 (Low)

Price

$1.59

Volume

64,052

Open

$1.60

Previous Close

$1.59

Daily Range

$1.58 - $1.67

52-Week Range

$1.17 - $2.71

Estimated Earnings Date

Sep 17, 2026

IPHA News

male scientist looking through microscope

Why Shares of Innate Pharma Jumped Thursday

James HalleyJun 8, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innate Pharma

Innate Pharma S.A. is a biotechnology firm based in Marseille, France, specializing in the discovery and development of therapeutic antibodies. Founded in 1999, the company primarily focuses on oncology indications while also addressing inflammatory diseases and viral infections through its innovative clinical-stage pipeline.

Products and Services
  • Lacutamab (IPH4102): Phase II trials for cutaneous T-cell lymphoma
  • Monalizumab: Phase III immune checkpoint inhibitor for advanced solid tumors
  • Avdoralimab (IPH5401): Phase II monoclonal antibody for COVID-19 and inflammatory conditions
Growth Outlook
  • Strong pipeline with multiple assets in advanced clinical trials
  • Strategic collaborations with major industry players enhance market reach
  • Focus on oncology and inflammatory diseases aligns with growing healthcare needs
Financial Highlights
  • Recent quarterly revenue of €3.16 million, showing potential growth
  • Trailing twelve months (TTM) net income margin of -45.54%, indicating ongoing investment in R&D
  • Cash and short-term investments of €10.89 million, providing operational liquidity
Innate Pharma S.A. is positioned in a dynamic sector with a robust pipeline of therapeutic candidates. The company's strategic partnerships and focus on high-demand therapeutic areas may provide significant opportunities for growth. Recent financial data reflects ongoing investments in research and development, which are crucial for long-term success in the biotechnology industry. The current cash position supports operational needs while the clinical advancements in the pipeline may lead to future revenue generation.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

163

CEO

Jonathan Dickinson, MBA

Website

www.innate-pharma.com

Headquarters

Marseille, PAC 13009, FR

IPHA Financials

Key Financial Metrics (TTM)

Gross Margin

1770.35%

Operating Margin

-5133.30%

Net Income Margin

-4554.32%

Return on Equity

152.56%

Return on Capital

-6150.49%

Return on Assets

-136.66%

Earnings Yield

-37.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$177.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.70M

Volume

64.05K

Avg. Volume

151.99K

Financials (TTM)

Gross Profit

€32.14M

Operating Income

-€100.54M

EBITDA

-€98.34M

Operating Cash Flow

-€88.69M

Capital Expenditure

-€347.61K

Free Cash Flow

-€89.04M

Cash & ST Invst.

€10.89M

Total Debt

€20.20M

Innate Pharma Performance Analysis

Innate Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 52,107,307264.0%
20232023-12-31EUR 56,110,9817.7%
20242024-12-31EUR 13,653,101-75.7%
20252025-12-31EUR 3,145,347-77.0%
Innate Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-97.8%
Q22025-06-301660.9%
Q42025-12-31-142.7%
Q22026-06-30252.3%
Innate Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.77-2.3%
20232023-12-31EUR -0.10-86.7%
20242024-12-31EUR -0.66549.2%
20252025-12-31EUR -0.62-6.2%
Innate Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-313.2%
Q22025-06-3016.7%
Q42025-12-31-20.0%
Q22026-06-3030.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€3.16M

-74.4%

Gross Profit

€0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$177.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.09M

N/A

Employees

163

N/A

Net Income

-€19.89M

+19.7%

EBITDA

-€21.23M

+17.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€10.89M

-88.1%

Total Debt

€20.20M

-43.1%

Accounts Receivable

€4.58M

-66.8%

Inventory

€0.00

N/A

Long Term Debt

€9.41M

-64.6%

Short Term Debt

€10.79M

+20.8%

Return on Assets

-1.37%

N/A

Return on Invested Capital

-28.60%

N/A

Free Cash Flow

-€21.42M

-878.0%

Operating Cash Flow

-€21.33M

-802.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MOLNMolecular Partners AG
$4.14+5.88%
CGENCompugen Ltd.
$2.34-1.68%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$6.34-7.04%
MISTMilestone Pharmaceuticals Inc.
$0.82-5.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About IPHA

What is the current price of Innate Pharma?

Innate Pharma is trading at $1.59 per share.

What is the 52-week range for Innate Pharma?

Over the past 52 weeks, Innate Pharma has traded between $1.17 and $2.71.

How much debt does Innate Pharma have?

As of the most recent reporting period, Innate Pharma reported total debt of €26.51M.

How much cash does Innate Pharma have on hand?

Innate Pharma reported €32.99M in cash and cash equivalents in its most recent financial results.

What is Innate Pharma’s dividend yield?

Innate Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services